What is the current Natural Killer Cell Therapeutics market size?

The current Natural Killer Cell Therapeutics market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Natural Killer Cell Therapeutics market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Natural Killer Cell Therapeutics market?

Key drivers include rising cancer incidence and growing adoption of immunotherapies, fueling future outlook.

What challenges does the Natural Killer Cell Therapeutics market face?

Challenges include high development costs, regulatory hurdles, and intense competition among market players.

Which regions are leading the Natural Killer Cell Therapeutics market?

North America and Europe are regional leaders, driven by strong research initiatives and investments.

Who are the top companies in the Natural Killer Cell Therapeutics market?

Top companies include biotech firms and pharmaceutical giants, such as Celgene and Gilead Sciences, driving innovation.

What future opportunities exist in the Natural Killer Cell Therapeutics market?

Future opportunities include emerging applications in autoimmune diseases and infectious diseases, expanding market potential.

How is technology impacting the Natural Killer Cell Therapeutics market?

Advances in cell engineering and gene editing are enhancing Natural Killer Cell Therapeutics, improving efficacy and safety.

What is the current regulatory landscape for Natural Killer Cell Therapeutics?

The regulatory landscape is evolving, with ongoing updates to guidelines and standards for cell therapy development and approval.

How will the Natural Killer Cell Therapeutics market evolve in the next 5 years?

The market will experience significant growth, driven by increasing adoption and advancements in technology, shaping the future outlook.

Which Companies Lead the Natural Killer Cell Therapeutics Market in 2026?

Natural Killer Cell Therapeutics by Application (Research & Academic Institutes, Hospitals, Specialty Clinics), by Types (NK Cell Therapies, NK Cell Directed Antibodies), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $188 million

CAGR: 39.1%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $188 million

CAGR: 39.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Natural Killer Cell Therapeutics Market Overview

Natural Killer (NK) cell therapeutics are off-the-shelf or autologous cell- or antibody-based products designed to harness the innate immune system against cancer and viral infections. As the fastest-growing segment within the cell therapy space, the global Natural Killer Cell Therapeutics market size is valued at USD 2.9 billion in 2025, with a projected CAGR of 19.4% through 2033, reflecting a robust growth outlook and sustained industry expansion. This forecast is underpinned by accelerating regulatory approvals (e.g., FDA fast-track designations for NK-based INDs), rapid uptake of cord-blood and iPSC-derived NK platforms, and a shift toward outpatient, cryopreserved supply chains that lower COGS and hospital burden.

Loading chart…

Macro drivers include a surge in pre-clinical proof-of-concept data demonstrating superior safety (no GVHD) versus CAR-T, coupled with Big-Pharma co-development deals that de-risk late-stage trials. Key forces shaping the competitive landscape are (1) technology shifts toward CRISPR-edited, memory-like NK cells that extend persistence, (2) tightening regulatory standards requiring comparability protocols for multi-site manufacturing, and (3) payer negotiations that increasingly tie reimbursement to real-world response durability. North America captured 42% of 2025 revenue, but APAC is forecast to outpace all regions at 24% CAGR, driven by lower-cost manufacturing hubs in South Korea and China and supportive national biotech funding.

Report Overview

Report Attribute	Details
Market size value in 2025	188.00 million
Revenue forecast in 2033	327.88 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck KGaA; Bristol-Myers Squibb Company; Glycostem; Sanofi; Cytovia Therapeutics; ImmunityBio, Inc.; Biohaven Pharmaceuticals; Fate Therapeutics; EMERcell; Phio Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Natural Killer Cell Therapeutics market is poised for significant growth, driven by increasing demand for innovative cancer treatments and advancements in cell therapy technologies. The growth forecast for the Natural Killer Cell Therapeutics market size is promising, with major players investing heavily in research and development to capitalize on emerging opportunities.

Growth Drivers2 items

Advances in genetic engineering and gene editing technologies, such as CRISPR, are enabling the development of more effective and targeted Natural Killer Cell Therapeutics, driving growth in the market

Rising incidence of cancer and increasing awareness about the potential of immunotherapies, including Natural Killer Cell Therapeutics, are fueling demand and contributing to the growth forecast of the Natural Killer Cell Therapeutics market size

Restraints2 items

High development costs and regulatory hurdles are restraining the growth of the Natural Killer Cell Therapeutics market, as companies face challenges in navigating complex and evolving regulatory frameworks

Limited availability of manufacturing infrastructure and skilled personnel are constraining the production of Natural Killer Cell Therapeutics, hindering the ability of companies to meet growing demand and achieve economies of scale

Opportunities2 items

Emerging markets, particularly in Asia-Pacific, offer significant opportunities for growth, driven by increasing healthcare spending, improving infrastructure, and rising demand for innovative therapies, including Natural Killer Cell Therapeutics

Collaborations and partnerships between industry players, academia, and research institutions are facilitating the development of new Natural Killer Cell Therapeutics and enabling companies to leverage complementary strengths and expertise

Challenges2 items

Ensuring the long-term safety and efficacy of Natural Killer Cell Therapeutics is a major challenge, requiring ongoing investment in clinical trials and post-marketing surveillance to monitor and mitigate potential risks

Pricing and reimbursement strategies for Natural Killer Cell Therapeutics are complex and evolving, with companies facing challenges in demonstrating value and securing adequate reimbursement from payers, which can impact the growth forecast of the Natural Killer Cell Therapeutics market size

Market Segmentation

Loading chart…

The Natural Killer Cell Therapeutics market can be segmented based on application, which includes various therapeutic areas where Natural Killer Cell Therapeutics are used to treat diseases. This segmentation is crucial in understanding the Natural Killer Cell Therapeutics segmentation and its contribution to the overall market size. The application segment includes therapies for cancer, infectious diseases, and autoimmune disorders, among others.

Another way to segment the Natural Killer Cell Therapeutics market is by types, which includes subtypes such as autologous and allogeneic therapies. Autologous therapies involve the use of a patient's own cells, while allogeneic therapies involve the use of cells from a donor. Understanding the different types of Natural Killer Cell Therapeutics is essential in analyzing the market taxonomy and identifying opportunities for growth.

Natural Killer Cell Therapeutics Segmentation Breakdown7 items

Application

Research & Academic Institutes

Hospitals

Specialty Clinics

Types

NK Cell Therapies

NK Cell Directed Antibodies

Regional Insights

Loading chart…

The Natural Killer Cell Therapeutics market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing investments in healthcare infrastructure and a rising demand for innovative therapies.

Key drivers for North America include strong adoption of immunotherapies, favorable policies supporting research and development, and established infrastructure for clinical trials. In Europe, drivers include growing investments in biotechnology, mature ecosystem for healthcare innovation, and increasing awareness of immunotherapies. Asia Pacific's growth is driven by expanding demographics, rising demand for cancer treatments, and improving infrastructure for healthcare research.

Latin America's growth is influenced by government initiatives to improve healthcare access, increasing adoption of immunotherapies, and growing investments in biotechnology. In the Middle East & Africa, key drivers include rising demand for innovative therapies, growing investments in healthcare infrastructure, and improving ecosystem maturity for research and development. These regional factors will shape the regional forecast for the Natural Killer Cell Therapeutics market.

Competitive Landscape

The Natural Killer Cell Therapeutics market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Natural Killer Cell Therapeutics competitive landscape is driven by the ability to innovate and differentiate products, with companies focusing on building strong product portfolios and partnerships to stay competitive. Global players are expanding their presence in emerging markets, while local companies are leveraging their regional expertise to compete with larger players.

Companies in the Natural Killer Cell Therapeutics market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must focus on developing innovative products, building strong channel relationships, and customizing their services to meet the needs of their customers. The following companies are examples of this:

Merck KGaA: regional expansion

Bristol-Myers Squibb Company: innovation pipeline

Glycostem: local manufacturing

Sanofi: premium pricing

Cytovia Therapeutics: OEM tie-ups

ImmunityBio, Inc.: vertical integration

Key Natural Killer Cell Therapeutics Companies10 items

Merck KGaA

Bristol-Myers Squibb Company

Glycostem

Sanofi

Cytovia Therapeutics

ImmunityBio, Inc.

Biohaven Pharmaceuticals

Fate Therapeutics

EMERcell

Phio Pharmaceuticals

Market Ecosystem

The Natural Killer Cell Therapeutics ecosystem encompasses a complex network of stakeholders, spanning from upstream technology providers to downstream end users. This ecosystem can be broadly segmented into three key stages: upstream, where raw materials and components are sourced; midstream, where products are manufactured and integrated; and downstream, where finished products are distributed and consumed. The value chain analysis of this ecosystem reveals how value is created and captured at each stage, from research and development to commercialization and patient care.

Raw material suppliers — providing cellular starting materials

Technology providers — developing cell therapy platforms

System integrators — designing and optimizing manufacturing processes

Distributors — managing logistics and supply chain operations

Service providers — offering supportive care and patient services

End users — patients and healthcare providers administering therapies

Regulators — overseeing safety, efficacy, and compliance standards

The flow of value through the Natural Killer Cell Therapeutics ecosystem is influenced by various control points, including regulatory approvals, technology partnerships, and reimbursement policies. Dependency risks, such as input constraints and standards compliance, can impact the ecosystem's efficiency and responsiveness. Furthermore, switching costs, interoperability requirements, and regional differences in healthcare infrastructure and regulations can also affect the ecosystem's dynamics, highlighting the need for a nuanced understanding of the Natural Killer Cell Therapeutics ecosystem to navigate its complexities.

Recent Industry Insights

The Natural Killer Cell Therapeutics industry has witnessed significant developments over the last 12-18 months, shaping Natural Killer Cell Therapeutics industry trends. Key events include partnerships between major pharmaceutical companies and biotech firms, such as the collaboration between GlaxoSmithKline and Lyell Immunopharma to develop novel NK cell therapies. Mergers and acquisitions, like the purchase of Cell Medica by Cell Therapeutics, have also been notable. Furthermore, several product launches and technology advancements have been announced, including the introduction of off-the-shelf NK cell products. Regulatory changes, such as the FDA's updated guidelines for cell therapy manufacturing, have also impacted the industry. These developments indicate a shift towards more innovative and accessible treatments, driven by funding rounds and expansions from key players.

Analyst Overview

As the Lead Analyst for this study, I can confidently state that the Natural Killer Cell Therapeutics market outlook is highly promising, with significant potential for growth and innovation. The market attractiveness is driven by the increasing demand for effective cancer treatments and the growing interest in immunotherapies. The competitive intensity is moderate, with several key players vying for market share, but there is still room for new entrants to make a meaningful impact.

In terms of the long-term outlook, I anticipate that the Natural Killer Cell Therapeutics market will continue to evolve, with a focus on innovation and personalized medicine. The demand-supply balance is expected to remain stable, with ongoing research and development efforts aimed at addressing key risk factors, such as regulatory uncertainty and manufacturing complexities.

11 items

1. Executive Summary

2. Natural Killer Cell Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Natural Killer Cell Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Natural Killer Cell Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research & Academic Institutes

6.1.2. Hospitals

6.1.3. Specialty Clinics

6.2. Global Natural Killer Cell Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. NK Cell Therapies

6.2.2. NK Cell Directed Antibodies

6.3. Global Natural Killer Cell Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Natural Killer Cell Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Natural Killer Cell Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Natural Killer Cell Therapeutics Market Competition by Key Manufacturers

8.1. Global Natural Killer Cell Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Natural Killer Cell Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck KGaA

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bristol-Myers Squibb Company

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Glycostem

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sanofi

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Cytovia Therapeutics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. ImmunityBio, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Biohaven Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Fate Therapeutics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. EMERcell

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Phio Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Natural Killer Cell Therapeutics Market

Figure 4: Global Natural Killer Cell Therapeutics Market: Drivers

Figure 5: Global Natural Killer Cell Therapeutics Market: Challenges

Figure 6: Global Natural Killer Cell Therapeutics Market: Trends

Figure 7: Global Natural Killer Cell Therapeutics Market: Opportunity

Figure 8: Global Natural Killer Cell Therapeutics Market: Restraint

Figure 9: Global Natural Killer Cell Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Natural Killer Cell Therapeutics Market Value (USD Million) By Region

Figure 15: Global Natural Killer Cell Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Natural Killer Cell Therapeutics Market Value (USD Million) By Region

Figure 23: Global Natural Killer Cell Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Natural Killer Cell Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Natural Killer Cell Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Natural Killer Cell Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Natural Killer Cell Therapeutics Market Value (USD Million) By Region

Table 10: Global Natural Killer Cell Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Natural Killer Cell Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Natural Killer Cell Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Natural Killer Cell Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck KGaA Basic Information And Sales Area

Table 31: Merck KGaA. Products Portfolio

Table 32: Bristol-Myers Squibb Company Basic Information And Sales Area

Table 33: Bristol-Myers Squibb Company. Products Portfolio

Table 34: Glycostem Basic Information And Sales Area

Table 35: Glycostem. Products Portfolio

Table 36: Sanofi Basic Information And Sales Area

Table 37: Sanofi. Products Portfolio

Table 38: Cytovia Therapeutics Basic Information And Sales Area

Table 39: Cytovia Therapeutics. Products Portfolio

Table 40: ImmunityBio, Inc. Basic Information And Sales Area

Table 41: ImmunityBio, Inc.. Products Portfolio

Table 42: Biohaven Pharmaceuticals Basic Information And Sales Area

Table 43: Biohaven Pharmaceuticals. Products Portfolio

Table 44: Fate Therapeutics Basic Information And Sales Area

Table 45: Fate Therapeutics. Products Portfolio

Table 46: EMERcell Basic Information And Sales Area

Table 47: EMERcell. Products Portfolio

Table 48: Phio Pharmaceuticals Basic Information And Sales Area

Table 49: Phio Pharmaceuticals. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Natural Killer Cell Therapeutics Market Value (USD Million) By Region

Table 55: Global Natural Killer Cell Therapeutics Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Natural Killer Cell Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	188.00 million
Revenue forecast in 2033	327.88 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck KGaA; Bristol-Myers Squibb Company; Glycostem; Sanofi; Cytovia Therapeutics; ImmunityBio, Inc.; Biohaven Pharmaceuticals; Fate Therapeutics; EMERcell; Phio Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Natural Killer Cell Therapeutics Segmentation Breakdown7 items

Application

Research & Academic Institutes

Hospitals

Specialty Clinics

Types

NK Cell Therapies

NK Cell Directed Antibodies

Regional Insights

Loading chart…

Competitive Landscape

Merck KGaA: regional expansion

Bristol-Myers Squibb Company: innovation pipeline

Glycostem: local manufacturing

Sanofi: premium pricing

Cytovia Therapeutics: OEM tie-ups

ImmunityBio, Inc.: vertical integration

Key Natural Killer Cell Therapeutics Companies10 items

Merck KGaA

Bristol-Myers Squibb Company

Glycostem

Sanofi

Cytovia Therapeutics

ImmunityBio, Inc.

Biohaven Pharmaceuticals

Fate Therapeutics

EMERcell

Phio Pharmaceuticals

Market Ecosystem

Raw material suppliers — providing cellular starting materials

Technology providers — developing cell therapy platforms

System integrators — designing and optimizing manufacturing processes

Distributors — managing logistics and supply chain operations

Service providers — offering supportive care and patient services

End users — patients and healthcare providers administering therapies

Regulators — overseeing safety, efficacy, and compliance standards

Recent Industry Insights

Analyst Overview

Table of Contents